Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGELLAN-3: Retreatment with Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin in HCV
NCT02939989Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2016
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label trial of glecaprevir + pibrentasvir in hepatitis C (HCV) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Sustained Virologic Response 12 Weeks Post-treatment. Started Nov 2016; status: completed.
02
Drugs
glecaprevir + pibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02939989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939989.